1-2 of 2
Malin Sydvander, MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Enrique M. Ocio, MDPhD, Yvonne A. Efebera, MD MPH, Roman Hájek, MD PhD, Miquel Granell, MD, Vladimir Maisnar, MD, Jan Straub, MD, Jean-Richard Eveillard, MD, Lionel Karlin, MD, Vincent Ribrag, MD, María-Victoria Mateos, MD PhD, Albert Oriol, Malin Sydvander, MSc, Stefan Norin, MD, Sofia Mannikko, MSc, Luděk Pour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-135991
Published: 2020
Journal Articles

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

Enrique M. Ocio, Yvonne A. Efebera, MD MPH, Miquel Granell, MD, Roman Hajek, MD, Vladimir Maisnar, MD, Lionel Karlin, MD, María-Victoria Mateos, MD PhD, Paul G. Richardson, MD, Albert Oriol, MD, Stefan Norin, MD, Malin Sydvander, MSc, Jakob Obermüller, MSc, Luděk Pour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3124.
https://doi.org/10.1182/blood-2019-124815
Published: 2019